North Texas Chapter

www.lls.org/ntx

Lone Star Blood Cancer Conference


2014 LONE STAR BLOOD CANCER CONFERENCE


Thank you for attending the 9th annual Lone Star Blood Cancer Conference. 
We hope you found it eduational and informational. 

Below you can download the presentations by clicking on the presenation title. Only those speakers who provided us with their presenation are available. Presentation version may differ from the one used the day of the conference if the speaker changed the presentation after submitting it to us.

 

2014 Lone Star Blood Cancer Conference Agenda


The Leukemia & Lymphoma Society 2014: Progress, Promise and Prospects
Scott Riccio, Senior Vice President, Patient Access and Advocacy
Nicole Bell, Southwest Region Mission Director
The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society - Get Involved
Tim Durst, The Leukemia & Lymphoma Society National Board President

Blood Cancer Research & Treatment ? A New Revolution

Michael Keating, M.B., B.S. - MD Anderson Cancer Center, Houston

Morning Breakout Sessions
A. Acute Leukemias - Updates from the American Society of Hematology (ASH®) Annual Meeting and Disease Management
Robert Collins, Jr. M.D., F.A.C.P. - University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas

B. Chronic Myelogenous Leukemia - Updates from the ASH® Annual Meeting and Disease Management
Luis Pineiro, M.D. - Texas Oncology at Baylor Charles A. Sammons Cancer Center, Dallas
Breakout provided by Pfizer 

C. Chronic Lymphocytic Leukemia - Updates from the ASH® Annual Meeting and Disease Management
Michael Keating, M.B., B.S. - MD Anderson Cancer Center, Houston
Breakout provided by Teva

D. The Science and Economics of Chemotherapy Part 1
   
The Science and Economics of Chemotherapy Part 2 
 
Klaus Hollmig, M.D. - UT Southwestern Simmons Cancer Center Plano-Richardson
Catherine Credeur, LMSW, OSW-C - UT Southwestern Harold C. Simmons Cancer Center
Melissa Neves - UT Southwestern Harold C. Simmons Cancer Center

E. I'm Not Crazy! I Just Have Cancer!
Joel Marcus, PsyD Director, Psychosocial Oncology & Palliative Care Services - Ochsner Cancer Institute, New Orleans, LA 

F. New Therapies in Pediatric & Adolescent Lymphoma
Martha Stegner, M.D. - Children's Medical Center, Dallas 

2:15 p.m. Afternoon Breakout Sessions
A. Multiple Myeloma - Updates from the ASH® Annual Meeting and Disease Management
Larry Anderson, M.D. - University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
Breakout provided by Millennium

B. Non Hodgkin Lymphoma - Updates from the ASH® Annual Meeting and Disease Management
M. Yair Levy, M.D. - Texas Oncology at Baylor Charles A. Sammons Cancer Center, Dallas
Breakout provided by Texas Oncology

C. Hodgkin Lymphoma - Updates from the ASH® Annual Meeting and Disease Management
Brian Berryman, M.D. - Baylor Charles A. Sammons Cancer Center, Dallas
Breakout provided by Sanofi

D. Treating Quality of Life (QOL) Issues in Hematologic Malignancies
Laurence H. Altshuler, M.D. - Cancer Treatment Centers of America, Tulsa, OK
Breakout provided by Cancer Treatment Centers of America

E. Physical Activity During and After Cancer Treatment: The Benefits and Potential Barriers
Kim Barker, M.D. - University of Texas Southwestern Medical Center, Dallas

F. Research Updates in Pediatric Cancer 
Maurizio Ghisoli, M.D. - Medical City Children?s Hospital, Dallas

3:30 p.m. Afternoon Breakout Sessions
A. Myelodysplastic Syndromes - Updates from the ASH® Annual Meeting and Disease Management
Prapti Patel, M.D. - University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas

B. Cultivating Optimal Health with Integrative Medicine
Claudia E. Harsh, MD Texas Oncology; Integrative Medicine and Medical Acupuncture at Cvetko Integrative Medicine Program at Baylor University Medical Center

C. Myeloproliferative Neoplasms* - Understanding Your Disease & Treatment Options
Karel Dicke, M.D., Ph.D. - Arlington Cancer Center, Arlington, TX
Breakout provided by Incyte

D. Overview of Late Effects of Therapy for Childhood & Young Adult Cancer
(target audience - 18-50 year old childhood cancer survivors)
Angela Orlino, M.D. - Children's Medical Center, Dallas

E. Role of Immune Therapy in the Treatment of Pediatric & Adolescent Leukemia 
Anish Ray, M.D. - Cook Children's Medical Center, Fort Worth


* Myeloproliferative Neoplasms include Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF).

ASH® is a registered trademark of the American Society of Hematology. This meeting is not sponsored, sanctioned by, or part of the 55th Annual Meeting of the American Society of Hematology"



C
ONTINUING EDUCATION CREDITS
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 5.5 continuing education contact hour(s) through the California Board of Registered Nursing.
The Leukemia & Lymphoma Society (LLS), provider number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org Approved Continuing Education Program (ACE). Approval Period: 12/2011-12/2014. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 5.5 CE clinical clock hour(s). Upon completion of this program and submission of the activity evaluation, a certificate of completion will
be issued to you following the program.
Partial credit WILL NOT be offered.

Learning Objectives

 

 

 

THANK YOU TO OUR SPONSORS!

Millennium

Celgene

Genentech

Teva Oncology

          CTCA

 

last updated on Wednesday, March 12, 2014
btn_sharethis